N-myristoyltransferase inhibitors as potential antifungal drugs

Drugs of the Future

Volumn 28, Issue 2, 2003, Pages 143-152

  Ohtsuka, Tatsuo ^a   Aoki, Yuko ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMOTETRADECANOIC ACID; ANTIFUNGAL AGENT; BENZOFURAN DERIVATIVE; BENZOFURAN INHIBITOR; BENZOTHIAZOLE; BENZOTHIAZOLE INHIBITOR; CP 123457; FLUCONAZOLE; MYRISTIC ACID DERIVATIVE; PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; RO 09 4879; SC 58272; SC 61213; TOLUENESULFONAMIDE DERIVATIVE; TOLUENESULFONAMIDE INHIBITOR; UK 356417; UK 362091; UK 370485; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0037697840     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.02.715958     Document Type: Review

References (60)

1. Pfaller, M.A., Jones, R.N., Messer, S.A., Edmond, M.B., Wenzel R.P. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency due to occurrence and antifungal susceptibility in the SCOPE Program, Diag Microbiol Infect Dis 1998, 31: 327-32.
2. Pfaller, M.A. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996, 22 (Suppl. 2): S89-94.
3. Garber, G. An overview of fungal infections. Drugs 2001, 61 Suppl 1: 1-12.
4. Denning, D.W. Early diagnosis of invasive aspergillosis. Lancet 2000, 355: 423-4.
5. Wald, A., Leisenring, W., Van Burik, J.A., Bowden, R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175: 1459-66.
6. Patrick, G.L. (Ed.). The why and the wherefore. In: An Introduction to Medicinal Chemistry. Oxford University Press: New York 1995, 12-4.
7. St. Geogiev, V. (Ed.). Fungal cell envelope and mode of action antimycotic agents. In: Infectious Diseases in Immunocom-promised Hosts. CRC Press: Boca Raton 1998, 741-61.
8. Lampen, J.O. Amphotericin B and other polyenic antifungal antibiotics. Am J Clin Pathol 1969, 52: 138-46.
9. Kaloyanides, G.J. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant Suppl 1994, 4: 130-4.
10. Sabra, R., Branch, R.A. Amphotericin B nephrotoxicity. Drug Safety 1990, 5: 84-108.
11. Sawaya, B.P., Briggs, J.P., Schermann, J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 1995, 6: 154-64.
12. Groll, A.H., De Lucca, A.J., Walsh, T.J. Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol 1998, 6: 117-24.
13. Bossche, H.V. Biochemical targets for antifungal azole derivatives: Hypothesis on the mode of action. Curr Topics Med Mycol 1983, 9: 321-56.
14. Benedetti, M.S., Bani, M. Metabolism-based drug interactions involving oral azole antifungals in humans. Drug Metab Rev 1999, 31: 665-717.
15. Denning, D.W. Echinocandins and pneumodandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997, 40: 611-4.
16. Georgopapadakou, N.H., Tkacz, J.S. The fungal cell wall as a drug target. Trends Microbiol 1995, 3: 98-105.
17. Georgopapadkou, N.H. Update on antifungals targeted to cell wall: Focus on beta-1,3-glucan synthase. Exp Opin Invest Drugs 2001, 10: 269-80.
18. Boutin, J.A. Myristoylation. Cell Signal 1997, 9: 15-35.
19. Bhatnagar, R.S., Gordon, J.I. Understanding covalent modifications of proteins by lipids: Where cell biology and biophysics mingle. Trends Cell Biol 1997, 7: 14-20.
20. McLaughlin, S., Aderem, A. The myristoyl-electrostatic switch: A modulator of reversible protein-membrane interactions, Trends Biochem Sci 1995, 20: 272-6.
21. Gordon, J. I., Duronio, R.J., Rudnick, D.A., Adams, S.P., Gokel, G.W. Protein N-myristoylation. J Biol Chem 1991, 266: 8647-50.
22. Johnson, D.R., Bhatnagar, R.S., Knoll, L.J., Gordon, J.I. Genetic and biochemical studies of protein N-myristoylation. Annu Rev Biochem 1994, 63: 869-914.
23. Stearns T., Kahn, R.A., Botstein, D., Hoyt, M.A. ADP ribosylation factor is an essential protein in Saccharomyces cerevisiae and is encoded by two genes. Mol Cell Biol 1990, 10; 6690-9.
24. Herman, P.K., Stack, J.H., DeModena, J.A., Emr, S.D. A novel protein kinase homolog essential for protein sorting to the yeast lysosome-like vacuole. Cell 1991, 64: 425-37.
25. Weinberg, R.A., McWherter, C.A., Freeman, S.K., Wood, D.C., Gordon, J.I., Lee, S.C. Genetic studies reveal that myristoylCoA:protein N-myristoyltransferase is an essential enzyme in Candida albicans. Mol Microbiol 1995, 16: 241-50.
26. Lodge, J.K., Jackson-Machelski, E., Toffaletti, D.L., Perfect, J.R., Gordon, J.I. Targeted gene replacement demonstrates that myristoyl-CoA:protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans, Proc Natl Acad Sci USA 1994, 91: 12008-12.
27. Duronio, R.J., Towler, D.A., Heuckeroth, R.O., Gordon, J.I. Disruption of the yeast N-myristoyl transferase gene causes recessive lethality. Science 1989, 243: 796-800.
28. Nakayama, H., Mio, T., Nagahashi, S., Kokado, M., Arisawa, M., Aoki, Y. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun 2000, 68: 6712-9.
29. Rocque, W.J., McWherter, C.A., Wood, D.C., Gordon, J.I. A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J Biol Chem 1993, 268: 9964-71.
30. Devadas, B., Zupec, M.E., Freeman, S.K. et al. Design and syntheses of potent and selective dipeptide inhibitors of Candida albicans myristoyl-CoA:protein N-myristoyltransferase. J Med Chem 1995, 38: 1837-40.
31. Devadas, B., Freeman, S.K., McWherter, C.A., Kuneman, D.W., Vinjamoori, D.V., Sikorski, J.A. A chiral recognition element with an unusual size constraint affects the potency and selectivity for peptidomimetic inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase. Bioorg Med Chem Lett 1996, 6: 1977-82.
32. Brown, D.L., Devadas, B., Lu, H. et al. Replacements for lysine in L-seryl-L-lysyl dipeptide amide inhibitors of Candida albicans myristoyl-CoA:protein N-myristoyltransferase. Bioorg Med Chem Lett 1997, 7: 379-82.
33. Nagarajan, S.R., Devadas, B., Zupec, M.E. et al. Conformationally constrained [p-(omega-aminoalkyl)phenacetyl]-L-seryl-L-lysyl dipeptide amides as potent peptidomimetic inhibitors of Candida albicans and human myristoyl-CoA:protein N-myristoyltransferase. J Med Chem 1997, 40: 1422-38.
34. Devadas, B., Freeman, S.K., Zupec, M.E. et al. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoyl CoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity. J Med Chem 1997, 40: 2609-25.
35. Devadas, B., Freeman, S.K., McWherter, C.A. et al. Novel biologically active nonpeptidic inhibitors of myristoylCoA:protein N-myristoyltransferase. J Med Chem 1998, 41: 996-1000.
36. Sikorski, J.A., Devadas, B., Zupec, M.E. et al. Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase: A new approach to antifungal therapy. Biopolymers 1997, 43: 43-71.
37. Lodge, J.K., Jackson-Machelski, E., Higgins, M. et al. Genetic and biochemical studies establish that the fungicidal effect of a fully depeptidized inhibitor of Cryptococcus neoformans myristoyl-CoA:protein N-myristoyltransferase (Nmt) is Nmt-dependent. J Biol Chem 1998, 273:12482-91.
38. Parang, K., Knaus, E.E., Wiebe, L.I., Sardari, S., Daneshtalab, M., Csizmadia, F. Synthesis and antifungal activities of myristic acid analogs. Arch Pharm 1996, 329: 475-82.
39. Paige, L.A., Zheng, G., DeFrees, S.A., Cassady, J.M., Geahlen, R.L. Metabolic activation of 2-substituted derivatives of myristic acid to form potent inhibitors of myristoyl CoA:protein N-myristoyltransferase. Biochemistry 1999, 29: 10566-73.
40. Armour, D.R., Bell, A.S., Kemp, M.I., Edwards, M.P., Wood, A. Discovery of a novel series of non-peptidic fungal N-myristoyl transferase inhibitors. 221st ACS Natl Meet (April 1-5, San Diego) 2001, Abst MEDI-349.
41. Bell, A.S., Armour, D.R., Edwards, M.P., Kemp, M.I., Wood, A. Discovery of fungicidal N-myristoyl transferase inhibitors. 221st ACS Natl Meet (April 1-5, San Diego) 2001, Abst MEDI-350.
42. Karki, R.G., Kulkarni, V.M. A feature based pharmacophore for Candida albicans myristoylCoA:protein N-myristoyltransferase inhibitors. Eur J Med Chem 2001, 36: 147-63.
43. Karki, R.G., Kulkarni, V.M. Computer-aided design and synthesis of Candida albicans N-myristoyltransferase inhibitors as antifungal agents. Indian Drugs 2001, 38: 406-13.
44. Masubuchi, M., Kawasaki, K., Ebiike, H. et al. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 1. Bioorg Med Chem Lett 2001, 11: 1833-7.
45. Ebiike, H., Masubuchi, M., Liu, P. et al. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2. Bioorg Med Chem Lett 2002, 12: 607-10.
46. Kawasaki, K., Masubuchi, M., Morikami, K. et al. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3. Bioorg Med Chem Lett 2003, 13: 87-91.
47. Masubuchi, M., Ebiike, H., Kawasaki, K. et al. Design and synthesis of a new class of antifungal agents targeting fungal N-myristoyltransferase. 21st Symp Med Chem 10th Annu Meet Div Med Chem (November 28-30, Kyoto) 2001, Abst 1P-05.
48. Ebiike, H., Masubuchi, M., Kawasaki, K. Design and synthesis of novel N-myristoyltransferase inhibitors as antifungal agents. 224th ACS Natl Meet (August 18-22, Boston) 2002, Abst MEDI-56.
49. Morikami, K., Hasegawa, K., Sogabe, S. QSAR analysis of fungal N-myristoyltransferase inhibitors: Correlation between enzyme inhibitory activity and interaction energies calculated by abnitio molecular orbital methods. 224th ACS Natl Meet (August 18-22, Boston) 2002, Abst COMP-187.
50. Sogabe, S., Masubuchi. M., Sakata, K. et al. Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors. Chem Biol 2002, 9: 1119-28.
51. Hasegawa, K., Shindoh, H., Shiratori, Y. et al. Cassette dosing approach and quantitative structure-pharmacokinetic relationship study of antifungal N-myristoyltransferase inhibitors. J Chem Inf Comput Sci 2002, 42: 968-75.
52. Grinev, A.N., Mashkovskii, M.D., Kaverina, N.V. et al. 1-(2-Carbethoxy-3-methylbenzofuran-4-yloxy)-3-isopropylamino-2-propanol hydrochloride with antiarrhythmic and beta-adrenoblocking action. Russian Patent 1986, SU 671256.
53. Hunter C.A., Sanders, J.K.M. The nature of pai-pai interactions. J Am Chem Soc 1990, 112: 5525-34.
54. Kennedy, T. Managing the drug discovery/development interface. Drug Discov Today 1997, 2, 436-44.
55. Schmitt, H.J., Andrade, J., Edwards, Y.N., Bernard, E., Armstrong, D. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1990, 9: 832-5.
56. Masubuchi, K., Okada, T., Kohchi, M. et al. Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 1. Bioorg Med Chem Lett 2001, 11: 395-8.
57. Masubuchi, K., Okada, T., Kohchi, M. et al. Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2. Bioorg Med Chem Lett 2001, 11: 1273-6.
58. Berman, J., Halm, K., Adkison, K., Shaffer, J. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J Med Chem 1997, 40: 827-9.
59. Frick, L.W., Adkison, K.K., Wells-Knecht, K.J., Woollard, P., Higton, D.M. Cassette dosing: Rapid in vivo assessment of pharmacokinetics. PSTT 1998, 1: 12-8.
60. Olah, T.V., McLoughlin, D.A., Gilbert, J.D. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom 1997, 11: 17-23.